Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
488 active trials5 approved drugs31 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777211 | A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT07157033 | A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.(XER-001) | recruiting | Phase 1 / Phase 2 | 36 | Xerient PharmaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04896073 | Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04115163 | Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 67 | Anne NoonanOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04594772 | Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 32 | University of CincinnatiOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04887805 | Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT03851614 | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors(DAPPER) | active not recruiting | Phase 2 | 90 | University Health Network, TorontoOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05518903 | Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma | recruiting | Phase 2 | 130 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06576115 | Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer | recruiting | Phase 2 | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06168812 | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | active not recruiting | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07043270 | 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC | recruiting | Phase 2 | 35 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07748611 | SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial | not yet recruiting | Phase 2 | 125 | Northwestern UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05132504 | Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | recruiting | Phase 2 | 30 | Baylor College of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06921928 | Study for AZD4360 in Participants With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 31 | AstraZenecaINDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT04990609 | EUS-RFA PANCARDINAL-1 Trial | recruiting | Phase 2 | 60 | The University of Texas Health Science Center, HoustonOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | recruiting | Phase 2 | 226 | AstraZenecaINDUSTRY | 14 | Jul 29, 2026 | clinicaltrials |
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer(VIRAGE2) | recruiting | Phase 1 / Phase 2 | 6 | Theriva Biologics SLINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02905578 | A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) | completed | Phase 2 | 40 | University of IowaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)(AA NABPLAGEM) | completed | Phase 1 / Phase 2 | 17 | HonorHealth Research InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04669197 | Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer | completed | Phase 2 | 19 | HonorHealth Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07711067 | A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer(MATTERS-2) | not yet recruiting | Phase 2 / Phase 3 | 95 | ElmediXINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT03856658 | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | active not recruiting | Phase 2 | 14 | Corewell Health WestOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05053971 | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705919 | DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | active not recruiting | Phase 2 | 393 | Astellas Pharma Global Development, Inc.INDUSTRY | 13 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04233866 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | active not recruiting | Phase 2 | 176 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05355298 | ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 62 | Amplia Therapeutics LimitedINDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05726864 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors(AMPLIFY-7P) | active not recruiting | Phase 1 / Phase 2 | 158 | Elicio TherapeuticsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07678593 | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 222 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05632328 | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | active not recruiting | Phase 2 | 24 | Bruno BockornyOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2026source: clinicaltrials